HOME › DRUGS › AUTOLOGOUS GLIOMA TUMOR CELL LYSATES (INACTIVATED);ALLOGENEIC GLIOMA TUMOR CELL LYSATES (INACTIVATED);ALLOGENEIC GLIOMA TUMOR CELLS (INACTIVATED);AUTOLOGOUS GLIOMA TUMOR CELLS (INACTIVATED)
ACTIVE SUBSTANCE / INN

AUTOLOGOUS GLIOMA TUMOR CELL LYSATES (INACTIVATED);ALLOGENEIC GLIOMA TUMOR CELL LYSATES (INACTIVATED);ALLOGENEIC GLIOMA TUMOR CELLS (INACTIVATED);AUTOLOGOUS GLIOMA TUMOR CELLS (INACTIVATED)

Brand name(s): Sitoiganap
EMA LISTED
APPLICATION WITHDRAWN
Glioma;Gliosarcoma
ACTIVE SUBSTANCE
Autologous Glioma Tumor Cell Lysates (Inactivated);Allogeneic Glioma Tumor Cell Lysates (Inactivated);Allogeneic Glioma Tumor Cells (Inactivated);Autologous Glioma Tumor Cells (Inactivated)
REGULATORS
EMA
SPONSORS / MAH
Epitopoietic Research Corporation-Belgium (E.R.C.)
TOTAL APPLICATIONS
1
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
SitoiganapEpitopoietic Research Corporation-Belgium (E.R.C.)Application withdrawnGlioma;Gliosarcoma

FULL INTELLIGENCE ON AUTOLOGOUS GLIOMA TUMOR CELL LYSATES (INACTIVATED);ALLOGENEIC GLIOMA TUMOR CELL LYSATES (INACTIVATED);ALLOGENEIC GLIOMA TUMOR CELLS (INACTIVATED);AUTOLOGOUS GLIOMA TUMOR CELLS (INACTIVATED)

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →